How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure

Area of Science:

• Oncology
• Hematology
• Immunotherapy

Background:

• Relapsed or refractory large B-cell lymphoma (R/R LBCL) following chimeric antigen receptor T-cell (CAR-T) therapy presents a significant clinical challenge.
• Limited established treatment guidelines exist for this patient population, leading to poor prognoses.

Purpose of the Study:

• To review current and emerging treatment strategies for patients with R/R LBCL after CAR-T failure.
• To provide guidance on managing this unmet need in hematologic malignancies.

Main Methods:

• Literature review and expert opinion synthesis on post-CAR-T therapies for R/R LBCL.
• Evaluation of available standard-of-care (SOC) agents, checkpoint inhibitors, radiation therapy, and novel therapeutic modalities.

Main Results:

• While SOC agents like polatuzumab, tafasitamab, selinexor, and loncastuximab tesirine are FDA-approved, their efficacy in the post-CAR-T setting requires further data.
• Bispecific antibodies show encouraging response rates and manageable toxicity in clinical trials.
• Checkpoint inhibitors may benefit selected patients with low tumor burden or PD-L1 expression.
• Radiation therapy is an option for localized relapses.

Conclusions:

• Enrollment in clinical trials, especially those testing bispecific antibodies, is strongly recommended for patients with R/R LBCL post-CAR-T.
• Other cell therapies and stem cell transplantation (SCT) may be considered, but logistical challenges and potential toxicities need careful evaluation.